繁體中文
English
PharmaEssentia US
PharmaEssentia Japan
Panco
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia vera,new drug development,biologics,PIC/s GMP protein plant>
Mobile Button
Search>
About Us
Achievements
Management
Board
Partnership
Join Us
Locations
Privacy and Cookies Policy
Capabilities
R&D Center
Pipeline
Core Technology
R&D Focus
Manufacturing Site
Milestone
Facilities
Process and Critical Equipment
Focus
Hematology
P1101 in ET Phase III
Infectious Diseases
P1101 in HCV Phase III in Genotype 2 Study (A14-301)
Oncology
KX-ORAX-005 Oraxol in combination with Ramucirumab for Gastric, Gastro-esophageal or Esophageal Cancer
KX-ORAX-007 A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
PD-1 in HCC Phase I/II (IIT)
Dermatology
KX01 in Psoriasis
Resources
Patients & Healthcare
Patients & Healthcare Professionals
Medical Information
News
Latest News
Press Releases
Events
Investors
Financial Information
Shareholder’s Services
Stock Information
Announcement
FAQ
CSR
Sustainable operations
Corporate governance
Social responsibilities
Stakeholder relations
Contact
Language
繁體中文
English
日本語
Overseas Branch
PharmaEssentia US
PharmaEssentia Japan
Panco
Ropeginterferon alfa-2b
The predominantly single isomer long acting interferon alpha-2b
Development Pipeline
Press Releases
pharmaessentia